One option for macular degeneration cuts treatment costs from $2,000 to $50. April 4, 2011— -- One drug costs $50 per dose. The other costs $2,000 per dose. Now, new research shows that the drug ...

The Genentech Inc. eye drug Lucentis performed well in a late-stage study of patients with diabetic macular edema — a treatment that could be rejected in the United Kingdom — but the real insight ...

The Department of Veterans Affairs said it has stopped using the drug Avastin to treat eye disease, as it investigates concerns about serious infections and blindness from the drug, according to a ...

LOS ANGELES, Nov 28 (Reuters) - A U.S. Senator said on Wednesday he is investigating Genentech Inc's plan to stop supplying its cancer drug Avastin to pharmacies that divide vials of the medicine so ...

LOS ANGELES (Reuters) - Genentech Inc said on Thursday it will ban on November 30 direct purchases of Avastin by independent compounding pharmacies, which repackage the cancer drug as a low-cost ...

The widely used cancer drug Avastin could save the eyesight of tens of thousands of people with age-related macular degeneration of the wet form, British researchers said Friday. The drug provides an ...

(AP) The Food and Drug Administration is warning doctors about another counterfeit version of the cancer drug Avastin distributed in the U.S., the third case involving the best-selling Roche drug in ...

WASHINGTON - The maker of the widely prescribed cancer drug Avastin is warning doctors and patients about counterfeit vials that have been distributed in the U.S. Roche's Genentech unit said Tuesday ...